In vitro activity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020)
Clinical Microbiology and Infection · 2026-01 · 32 (1) · 102-109
DOI: 10.1016/j.cmi.2025.09.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026-01. Verfasst von Qingye Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Center, Zhejiang Center for Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical Col…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Sulbactam, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Medicine Center, Zhejiang Center for Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Department of Clinical Laboratory, Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, S…
- Center for General Practice Medicine, Department of Infectious Diseases, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address: yvys…
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
Zitieren
APA
Xu, Q., Liu, X., Liu, H., Yang, S., Lei, T., Hua, X., & Yu, Y. (2026). In vitro activity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020). Clinical Microbiology and Infection, 32(1), 102-109. https://doi.org/10.1016/j.cmi.2025.09.016
Vancouver
Xu Q, Liu X, Liu H, Yang S, Lei T, Hua X, et al. In vitro activity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020). Clinical Microbiology and Infection. 2026;32(1):102-109. doi:10.1016/j.cmi.2025.09.016
BibTeX
@article{Xu2026,
author = {Xu, Qingye and Liu, Xiaochen and Liu, Haiyang and Yang, Siyuan and Lei, Tailong and Hua, Xiaoting and Yu, Yunsong},
title = {In vitro activity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020)},
journal = {Clinical Microbiology and Infection},
year = {2026},
volume = {32},
number = {1},
pages = {102--109},
doi = {10.1016/j.cmi.2025.09.016}
}
EUVIMED